| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbffa3b81b3b862dc7220b5648f5f745 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G09F2003-0214 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G11B33-0411 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2003-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79c5beddfa30285ab3dda197bd4d4952
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33e72138013bd380214dabed4b332a96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10b39c24406e75fb43b940806db70af4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f28e54173847fb0c04bf384db771cbc1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_444bff70c46189f8ee8308d4799696cb |
| publicationDate |
2004-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20040069834-A |
| titleOfInvention |
Anticancer Drug Comprising Isoginkgetin or Their Pharmaceutically Acceptable Salts as an Active Ingredient |
| abstract |
The present invention is directed to an anticancer agent, particularly p53, and the inhibition of the PI3-kinase / Akt pathway, which are isolated from the leaves of Metaschequoia, with the active ingredient isoginggettin or a pharmaceutically acceptable salt thereof. It provides an anticancer agent with excellent growth inhibition and cell death promoting ability. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113143906-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100868702-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100928125-B1 |
| priorityDate |
2003-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |